BCX logo

Bioceltix S.A. Stock Price

WSE:BCX Community·zł542.2m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

BCX Share Price Performance

zł98.00
-12.00 (-10.91%)
zł98.00
-12.00 (-10.91%)
Price zł98.00

BCX Community Narratives

There are no narratives available yet.

Trending Discussion

No trending discussion available.

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with limited growth.

2 Risks
1 Reward

Bioceltix S.A. Key Details

zł0

Revenue

zł2.6m

Cost of Revenue

-zł2.6m

Gross Profit

zł14.4m

Other Expenses

-zł17.0m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Sep 23, 2026
-3.08
0%
0%
0%
View Full Analysis

About BCX

Founded
2016
Employees
46
CEO
Lukasz Bzdzion
WebsiteView website
bioceltix.com

Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company’s products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses. It also develops BCX-CM-Sec, a research project aimed at developing a cell-free biological drug to treat atopic dermatitis in dogs. The company was founded in 2016 and is headquartered in Wroclaw, Poland.

Recent BCX News & Updates

Recent updates

No updates